arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Aura Biosciences, Inc.

AURA

$7.73 ▲ +0.55 (+7.59%) at close

7 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Aura Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $466.4M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -82.5% ↘

FCF / Share $-1.41 ↗

Trailing P/E —

Price / Book 3.6x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 6, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-106.19M

↓ -22.2% —

FCF / Share Free cash flow per share

$-1.41

↑ +13.5% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	-0.6% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	9.3% Fair ↓ Fair Declining Year-over-year change in earnings per share Optimal: > 10%	1.5% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	78.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-22.2% Weak ↑ Weak Improving Year-over-year change in net income	-13.8% Weak ↑ Weak Improving Year-over-year change in net income	-30.0% Weak ↑ Weak Improving Year-over-year change in net income	-66.7% Weak Weak Year-over-year change in net income	-58.7% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	13.5% Fair ↓ Fair Declining Year-over-year change in free cash flow	-0.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	12.4% Fair Fair Year-over-year change in free cash flow	72.2% Excellent Excellent Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Effective Tax Rate (%) (%)	-0.1% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—
FCF / Net Income (x)	0.80x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.13x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-82.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-63.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-37.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-30.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-18.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	16.1% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-66.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-52.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-33.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-26.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-22.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-100.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-77.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-617%)	-57.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-481%)	-33.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-326%)	-30.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-300%)	-23.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-254%)	20.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+36%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Net Debt (USD)	$-59.52M	$-31.69M	$-41.06M	$-121.58M	$-149.06M	$-17.39M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-1.76	$-1.75	$-1.93	$-1.96	$-8.95	—	—
Free Cash Flow per Share (USD)	$-1.41	$-1.63	$-1.63	$-1.86	$-6.69	—	—
Book Value per Share (USD)	$2.15	$3.04	$4.58	$5.18	$5.21	$-285.24	—
Tangible Book Value per Share (USD)	$2.15	$3.04	$4.58	$5.18	$5.21	$-285.24	—
Basic Weighted Avg Shares (shares)	60.34M	49.65M	39.62M	29.94M	5.16M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$131.36M	$145.71M	$219.44M	$186.25M	$146.35M	$15.79M	—
Total Equity (USD)	$136.91M	$151.97M	$225.85M	$195.58M	$152.31M	$-108.71M	$-87.41M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	$1.13M	$1.22M	$1.29M	$1.18M	$831.00K	$831.00K	—
Net Income, GAAP (USD)	$-106.19M	$-86.92M	$-76.41M	$-58.76M	$-35.25M	$-22.21M	—
Operating Cash Flow (USD)	$-84.74M	$-79.81M	$-63.85M	$-54.60M	$-32.41M	$-24.32M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Aura Biosciences, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare AURA with peers